目的:“2024AHA/ACC/AMSSM/HRS/PACES/SCMR肥厚型心肌病管理指南”为指导临床医生管理肥厚型心肌病提供了建议。
方法:从2022年9月14日至2022年11月22日进行了全面的文献检索,包括研究,reviews,以及PubMed以英文发表的关于人类受试者的其他证据,EMBASE,Cochrane图书馆,医疗保健研究和质量机构,以及与本指南相关的其他选定数据库。其他相关研究,发布至2023年5月23日,在指南编写过程中,也由写作委员会审议并添加到证据表中,在适当的地方。
■肥厚型心肌病仍然是全球人群中常见的遗传性心脏病。“2020AHA/ACC肥厚型心肌病患者诊断和治疗指南”的建议已更新,并有新的证据指导临床医生。
OBJECTIVE: The \"2024 AHA/ACC/AMSSM/HRS/PACES/SCMR
Guideline for the Management of Hypertrophic Cardiomyopathy\" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.
METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this
guideline. Additional relevant studies, published through May 23, 2023, during the
guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.
UNASSIGNED: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the \"2020 AHA/ACC
Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy\" have been updated with new evidence to guide clinicians.